Hyperphagia, Prader-Willi Syndrome
Conditions
Keywords
Prader-Willi Syndrome, Hyperphagia
Brief summary
This study is a phase 2 randomized double blind 8-week treatment trial of intranasal OXT vs. placebo in 50 subjects aged 5 to 17 years with PWS in order to assess IN-OXT's affect on measurements of (1) eating behaviors (2) repetitive behaviors (3) weight and body composition (4) quality of life (5) salivary OXT and hormone levels (including ghrelin, pancreatic polypeptide, peptide YY, Glucagon-Like Peptide-1 (GLP-1), insulin, glucagon, testosterone, and estrogen). If superior to placebo, this data will add to the current knowledge that OXT is an effective treatment for hyperphagia as well as other symptoms of PWS. Funding Source- FDA OOPD
Detailed description
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder caused by lack of expression of paternally derived imprinted material on chromosome 15q11-q13. PWS is characterized by mild to moderate intellectual disabilities, repetitive/compulsive behaviors and rigidity, social cognition deficits and severe hypotonia at birth, followed by the onset of hyperphagia later in life. Obesity is responsible for the majority of the morbidity and mortality associated with PWS, and compulsive eating behaviors are most responsible for diminishing the quality of life for caregivers and family members. Oxytocin has been implicated in the pathophysiology of PWS and there have been small studies of intranasal oxytocin (IN-OXT) in this population. To date, however, studies have not been adequately powered to detect significance in target symptoms of hyperphagia and associated symptoms of individuals with PWS. The primary goal of this study is to examine the safety and efficacy of IN-OXT on hyperphagia, as measured by the Hyperphagia Questionnaire-Clinical Trails, from baseline to week 8. Currently, there are no effective treatments available to manage hyperphagia in patients with PWS. STUDY DESIGN: This is an 8-week double-blind, randomized study in 50 children with PWS aged 5-17. Participation involves 2 in-person visits to our program and 5 remote visits. Travel expenses will be reimbursed to participating families.
Interventions
Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
DRUGMatched Placebo
Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
Sponsors
Eric Hollander
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female pediatric outpatients aged 5 to 17 years 2. Must be in PWS nutritional phase 2b or 3 as determined by PI 3. Must be on growth hormone treatment and have been receiving stable doses of growth hormone treatment for at least 3 months prior to screening date. Treatment cannot have been interrupted for more than one week within 3 months of screening. 4. Diagnosis of PWS confirmed by patient medical records. 5. A score of at least moderate severity on the Hyperphagia Questionnaire for Clinical Trials at both screening and baseline visits. 6. Stable dosages of hormone treatments (including testosterone and estrogen supplements) for 4 weeks prior to randomization and for the duration of the study. 7. Stable dosages of metabolic treatments that could affect appetite (including metformin) for 4 weeks prior to randomization and for the duration of the study. 8. Physical exam and laboratory results that are within the normal range for individuals with PWS. 9. Presence of a parent/caregiver/guardian that is able to consent for their participation and complete assessments regarding the child's development and behavior change throughout the study.
Exclusion criteria
1. Exposure to any investigational agent in the 30 days prior to randomization. 2. Child not receiving growth hormone treatment 3. Children weighing less than 40 lbs 4. Children with unstable Type 2 Diabetes confirmed by Hemoglobin A1C levels at screening 5. Children with unstable medical co-morbidities at baseline. 6. Children with active upper respiratory infections at screening. 7. A primary psychiatric diagnosis other than Autism Spectrum Disorder (ASD), including bipolar disorder, psychosis, schizophrenia, Post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). These patients will be excluded due to potential confounding results. 8. Pregnant or lactating patients or patients who will not agree to use a double barrier method of contraception. IN-OXT has not been studied in pregnant or lactating women. 9. Females using an estrogen-based contraceptive. As an alternative to an estrogen based contraceptive, subjects will be counseled to use progesterone-based contraceptives; cervical cap; cervical sponges; or spermicidal foam in combination with a condom. Subjects will need to use a double barrier method to be in the study. 10. A medical condition that might interfere with the conduct of the study, confound interpretation of study results or endanger the subject's well-being. 11. A known diagnosis of Rett's Syndrome of Childhood Disintegrative Disorder or marked sensory impairment such as deafness or blindness. 12. Subjects who have changes in allied health therapies, behavioral or educational interventions within four weeks prior to randomization other than those associated with school holidays. 13. Subjects who have had changes in medications or medication doses of risperidone, aripiprazole, other antipsychotic medications, clonidine, guanfacine, stimulants or anti-convulsants within four weeks of randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in efficacy of peptide IN-OXT as measured by changes in hyperphagia from baseline will be assessed using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). HQ-CT is a caregiver-rated assessment comprised of 9-items that measures the frequency and intensity of hyperphagic behaviors, over the preceding two weeks, in participants with Prader-Willi Syndrome (PWS). The HQ-CT total score is created by summing the 9 item-level responses (ranging from 0 to 4) for a possible range of 0-36 with higher scores indicate more extreme hyperphagia. For purposes of this outcome measure, negative scores represent a decrease in hyperphagia from baseline and positive scores represent an increase in hyperphagia from baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Rigid Behavior | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in Rigid Behavior from baseline was assessed using the Montefiore-Einstein Rigidity Scale-Revised-Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is designed to assess 3 domains of rigid behavior in children with PWS: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity (e.g., verbal objection, tantrum, physical aggression). Four items are rated on a 5-point scale ranging from 0 (No/None) to 4 (Extreme/Extremely difficult) for each of the 3 domains. The domains are added yielding a possible Total Domain Score which could range from 0-48. For purposes of this outcome measure, a change in group mean score from baseline is summarized. A negative score is indicative of a decrease in rigid behaviors from baseline; whereas, a positive score is indicative of an increase in rigid behavior from baseline. |
| Change in Body Weight | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in body weight from baseline was determined by obtaining the participant's body weight, in kilograms, using a regularly calibrated scale. Change in body weights from baseline are summarized by study arm using basic descriptive statistics. A negative result indicates a decrease in body weight from baseline and may be associated with improved health-related outcomes including a decrease in hyperphagia. |
| Body Composition | 8 weeks | Body composition, in particular fat mass, was assessed using bioelectrical impedance analysis (BIA). BIA was conducted with equipment and oversight provided by the Einstein-Mount Sinai Diabetes Research Center. The equipment measured resistance in ohms which represents the resistance to a small alternating current passing through the body. These values are converted to body fat percentages using built-in software, after calibrating for variables, for purposes of reporting. Percentages are summarized by study arm using basic descriptive statistics. |
| Change in Body Mass Index (BMI) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in BMI from baseline will be calculated by dividing the participant's weight in kilograms by their height in meters squared (kg/m\^2). Change in mean BMI from baseline will summarized and reported using basic descriptive statistics. A negative BMI score may be indicative of a decrease in hyperphagia from baseline; whereas, a positive BMI score may be indicative of an increase in hyperphagia when compared to baseline. |
| Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire: Domain 1 (Physical Health) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in QOL/Caregiver burden was assessed using the 7-item Physical Health domain subscale of the WHOQOL-BREF questionnaire. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. Each item of the Physical Health domain was scored on a 5-point ordinal scale ranging from 1-5, for an overall possible raw scoring range of 7-35. A mean overall Physical Health score was calculated by summing the scores from the seven items (response values for 2 of the items are inversely-coded) and dividing by the total # of questions (7) for an algebraic mean. A transformed scale score was obtained by subtracting 7 (lowest possible score) from the raw score and dividing by 28 (possible raw score range). For purposes of this outcome measure change from baseline was reported. Increases in Physical Health scores from baseline were associated with higher physical health QOL and reduced caregiver physical burden. |
| Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 2 (Psychological Health) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in QOL/caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF measures 4 broad domains: Physical Health, Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver quantified the burden placed on the caregiver/family by the PWS disorder. For the Psychological Health domain (6 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Psychological Health score was calculated by summing the scores from 5 of the questions (#s 5, 6, 7, 11, and 19) and inverting the response value from Question #26 and adding it to the sum of the other 5 scores and dividing by the total number of questions (6). This result was multiplied by 4 to get a final Psychological Health domain score. Raw scoring ranges from 6-30; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden. |
| Change in Repetitive Behavior | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in Repetitive Behavior from baseline was determined using the Repetitive Behavior Scale Revised (RBS-R) score. The RBS-R is a 44-item form used to measure the full spectrum of repetitive behavior of participants. The child's parent will choose a score that describes how much of a problem the behavior has been over the last month on a 4-point scale ranging from 0 (Behavior does not occur) to 3 (Behavior occurs and is severe problem). The final question asks participants to lump together all behaviors described in the RBS-R, and provide a rating (0-100) for how much of a problem these repetitive behaviors are overall: 1 (Not a problem at all) to 100 (As bad as you can imagine). For purposes of this outcome, a change in group mean score from baseline is summarized. A negative score is indicative of a decrease in the frequency and severity of behavioral problems; whereas, a positive score is indicative of an increase in the frequency and severity of behavioral problems. |
| Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 4 (Environment) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in QOL and caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF is comprised of 26 items which measure 4 broad domains: Physical Health, Psychological Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. For the Environment domain (8 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Environment score was calculated by summing the scores from the 8 questions (#s 8, 9, 12, 13, 14, 23, 24, and 25) and dividing by the total number of questions (8). This result was multiplied by 4 to get a final Environmental domain score. Environment raw scoring ranges from 8-40; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden. |
| Change in Caregiver Strain | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in Caregiver Strain from baseline was assessed using the Caregiver Strain Questionnaire (CSQ). The CSQ is a 21-item measure of self-reported strain experienced by caregivers/families of youth with emotional problems. Responses to the CSQ are measured on a 5-point Likert scale measuring the impact of strain ranging from 1 = (Not at all) to 5 = (very much) for an overall possible scoring range of 21-105. For purposes of this outcome measure, a change in group mean score from baseline is summarized. A negative score is indicative of decreased caregiver/family strain from baseline; whereas, a positive score is indicative of increased caregiver/family strain from baseline. |
| Change in Aberrant Behavior | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in Aberrant Behavior from baseline was assessed using the Aberrant Behavior Checklist-Irritability 15-item subscale (ABC-I). The ABC-I subscale was completed by the caregiver on behalf of the child. At the suggestion of the FDA, the ABC-I subscale was included as a prospective assessment for suicidal ideation and behavior and inform investigators of trends toward increased irritability and disruptive behavior. ABC-I measures behavior on a 4-point severity scale where 0 = no problem at all, 1 = behavior is a problem but in a slight degree, 2 = problem is moderately serious, and 3 = problem is severe in degree, for an overall scoring range of 0-45. For purposes of this outcome, a change in group mean score from baseline is summarized. A negative ABC-I score is indicative of overall decreased irritability and disruptive behavior from baseline, whereas a positive ABC-I score is indicative of overall increased irritability and disruptive behavior from baseline. |
| Change in Salivary Oxytocin Concentration | From Baseline until collections at 1 hour (Day 1), Week 4 and Week 8 | Change in Salivary Oxytocin concentration levels from baseline were to have been collected. Salivary samples were to have been collected using the Oragene-Discover collection kit (ORG-500). If able, participants were to have spit saliva directly into the collection tube during an in office or remote visit, and subsequently transported to the clinical site during visit and later processed and submitted for analysis. Change in group mean concentrations from baseline was to have been summarized by study arm using basic descriptive statistics. Increases in concentrations of salivary oxytocin are generally correlated with central nervous system effects and an improvement in these symptoms. |
| Clinical Global Impression Scale - Improvement (CGI-I) | 8 weeks (measuring change over 8 weeks) | CGI-I is a clinician rated global measure of improvement that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline at the beginning of the intervention. The CGI-I consists of one query which is rated on a 7-point scale: Compared to the patient's condition at admission \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Scores are summarized by study arm using basic descriptive statistics. |
| Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 3 (Social Relationships) | From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks) | Change in QOL and caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF measures 4 broad domains: Physical Health, Psychological Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. For the Social Relationships domain (3 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Social Relationships score was calculated by summing the 3 scores (#s 20, 21, and 22) and dividing by the total number of questions (3). This result was multiplied by 4 to get a final Social Relationships domain score. Social Relationships raw scoring ranges from 3-15; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden. |
Countries
United States
Participant flow
Pre-assignment details
Eight (8) study participants who consented were not enrolled as they did not meet inclusion/exclusion criteria (screen failures) or withdrew prior to randomization into the study.
Participants by arm
| Arm | Count |
|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
Intranasal Oxytocin (IN-OXT): Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response. | 15 |
| Placebo Comparator: Matched Placebo Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
Matched Placebo: Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response. | 17 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawn by family | 0 | 2 |
Baseline characteristics
| Characteristic | Total | Placebo Comparator: Matched Placebo | Experimental: Intranasal Oxytocin (IN-OXT) |
|---|---|---|---|
| Age, Customized 13-18 years old | 3 Participants | 2 Participants | 1 Participants |
| Age, Customized 5-6 years old | 7 Participants | 5 Participants | 2 Participants |
| Age, Customized 7-12 years old | 22 Participants | 10 Participants | 12 Participants |
| Body Composition | 23.5 percentage of fat | 27.0 percentage of fat | 20.6 percentage of fat |
| Body Mass Index (BMI) | 19.5 kg/m^2 | 18.8 kg/m^2 | 20.2 kg/m^2 |
| Body Weight | 43.1 kilograms STANDARD_DEVIATION 26.9 | 45.2 kilograms STANDARD_DEVIATION 34.9 | 40.8 kilograms STANDARD_DEVIATION 17.9 |
| Height | 133.0 centimeters STANDARD_DEVIATION 17.6 | 130.4 centimeters STANDARD_DEVIATION 18.9 | 135.6 centimeters STANDARD_DEVIATION 16.3 |
| Race/Ethnicity, Customized American Indian/Alaskan Native | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black/African American | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Multiracial | 5 Participants | 3 Participants | 2 Participants |
| Race/Ethnicity, Customized Native Hawaiian/Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Unknown | 2 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 25 Participants | 13 Participants | 12 Participants |
| Region of Enrollment United States | 32 participants | 17 participants | 15 participants |
| Sex: Female, Male Female | 14 Participants | 8 Participants | 6 Participants |
| Sex: Female, Male Male | 18 Participants | 9 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 15 | 0 / 17 |
| other Total, other adverse events | 7 / 15 | 13 / 17 |
| serious Total, serious adverse events | 0 / 15 | 0 / 17 |
Outcome results
Primary
Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT)
Change in efficacy of peptide IN-OXT as measured by changes in hyperphagia from baseline will be assessed using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). HQ-CT is a caregiver-rated assessment comprised of 9-items that measures the frequency and intensity of hyperphagic behaviors, over the preceding two weeks, in participants with Prader-Willi Syndrome (PWS). The HQ-CT total score is created by summing the 9 item-level responses (ranging from 0 to 4) for a possible range of 0-36 with higher scores indicate more extreme hyperphagia. For purposes of this outcome measure, negative scores represent a decrease in hyperphagia from baseline and positive scores represent an increase in hyperphagia from baseline.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) | -6.08 score on a scale | Standard Deviation 5.65 |
| Placebo Comparator: Matched Placebo | Change in Efficacy of Peptide Intranasal Oxytocin (IN-OXT) | -6.64 score on a scale | Standard Deviation 5.05 |
Secondary
Body Composition
Body composition, in particular fat mass, was assessed using bioelectrical impedance analysis (BIA). BIA was conducted with equipment and oversight provided by the Einstein-Mount Sinai Diabetes Research Center. The equipment measured resistance in ohms which represents the resistance to a small alternating current passing through the body. These values are converted to body fat percentages using built-in software, after calibrating for variables, for purposes of reporting. Percentages are summarized by study arm using basic descriptive statistics.
Time frame: 8 weeks
Population: Data was missing or unable to be collected from 4 participants in the IN-OXT study arm and 8 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Body Composition | 23.5 percentage of fat |
| Placebo Comparator: Matched Placebo | Body Composition | 24.3 percentage of fat |
Secondary
Change in Aberrant Behavior
Change in Aberrant Behavior from baseline was assessed using the Aberrant Behavior Checklist-Irritability 15-item subscale (ABC-I). The ABC-I subscale was completed by the caregiver on behalf of the child. At the suggestion of the FDA, the ABC-I subscale was included as a prospective assessment for suicidal ideation and behavior and inform investigators of trends toward increased irritability and disruptive behavior. ABC-I measures behavior on a 4-point severity scale where 0 = no problem at all, 1 = behavior is a problem but in a slight degree, 2 = problem is moderately serious, and 3 = problem is severe in degree, for an overall scoring range of 0-45. For purposes of this outcome, a change in group mean score from baseline is summarized. A negative ABC-I score is indicative of overall decreased irritability and disruptive behavior from baseline, whereas a positive ABC-I score is indicative of overall increased irritability and disruptive behavior from baseline.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Aberrant Behavior | -5.33 score on a scale | Standard Deviation 6.75 |
| Placebo Comparator: Matched Placebo | Change in Aberrant Behavior | -1.77 score on a scale | Standard Deviation 5.95 |
Secondary
Change in Body Mass Index (BMI)
Change in BMI from baseline will be calculated by dividing the participant's weight in kilograms by their height in meters squared (kg/m\^2). Change in mean BMI from baseline will summarized and reported using basic descriptive statistics. A negative BMI score may be indicative of a decrease in hyperphagia from baseline; whereas, a positive BMI score may be indicative of an increase in hyperphagia when compared to baseline.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 1 participant in the IN-OXT arm and 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Body Mass Index (BMI) | 0.229 kg/m2 | Standard Deviation 1.26 |
| Placebo Comparator: Matched Placebo | Change in Body Mass Index (BMI) | -0.357 kg/m2 | Standard Deviation 0.911 |
Secondary
Change in Body Weight
Change in body weight from baseline was determined by obtaining the participant's body weight, in kilograms, using a regularly calibrated scale. Change in body weights from baseline are summarized by study arm using basic descriptive statistics. A negative result indicates a decrease in body weight from baseline and may be associated with improved health-related outcomes including a decrease in hyperphagia.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Body Weight | 0.585 kilograms | Standard Deviation 0.709 |
| Placebo Comparator: Matched Placebo | Change in Body Weight | -0.0669 kilograms | Standard Deviation 2.14 |
Secondary
Change in Caregiver Strain
Change in Caregiver Strain from baseline was assessed using the Caregiver Strain Questionnaire (CSQ). The CSQ is a 21-item measure of self-reported strain experienced by caregivers/families of youth with emotional problems. Responses to the CSQ are measured on a 5-point Likert scale measuring the impact of strain ranging from 1 = (Not at all) to 5 = (very much) for an overall possible scoring range of 21-105. For purposes of this outcome measure, a change in group mean score from baseline is summarized. A negative score is indicative of decreased caregiver/family strain from baseline; whereas, a positive score is indicative of increased caregiver/family strain from baseline.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Caregiver Strain | -1.32 score on a scale | Standard Deviation 1.05 |
| Placebo Comparator: Matched Placebo | Change in Caregiver Strain | -0.355 score on a scale | Standard Deviation 1.35 |
Secondary
Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire: Domain 1 (Physical Health)
Change in QOL/Caregiver burden was assessed using the 7-item Physical Health domain subscale of the WHOQOL-BREF questionnaire. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. Each item of the Physical Health domain was scored on a 5-point ordinal scale ranging from 1-5, for an overall possible raw scoring range of 7-35. A mean overall Physical Health score was calculated by summing the scores from the seven items (response values for 2 of the items are inversely-coded) and dividing by the total # of questions (7) for an algebraic mean. A transformed scale score was obtained by subtracting 7 (lowest possible score) from the raw score and dividing by 28 (possible raw score range). For purposes of this outcome measure change from baseline was reported. Increases in Physical Health scores from baseline were associated with higher physical health QOL and reduced caregiver physical burden.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 1 participant in the IN-OXT arm and 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire: Domain 1 (Physical Health) | -0.0714 score on a scale | Standard Deviation 2.89 |
| Placebo Comparator: Matched Placebo | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire: Domain 1 (Physical Health) | -0.929 score on a scale | Standard Deviation 3.47 |
Secondary
Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 2 (Psychological Health)
Change in QOL/caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF measures 4 broad domains: Physical Health, Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver quantified the burden placed on the caregiver/family by the PWS disorder. For the Psychological Health domain (6 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Psychological Health score was calculated by summing the scores from 5 of the questions (#s 5, 6, 7, 11, and 19) and inverting the response value from Question #26 and adding it to the sum of the other 5 scores and dividing by the total number of questions (6). This result was multiplied by 4 to get a final Psychological Health domain score. Raw scoring ranges from 6-30; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 1 participant in the IN-OXT arm and 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 2 (Psychological Health) | -0.500 score on a scale | Standard Deviation 1.99 |
| Placebo Comparator: Matched Placebo | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 2 (Psychological Health) | -1.86 score on a scale | Standard Deviation 3.9 |
Secondary
Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 3 (Social Relationships)
Change in QOL and caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF measures 4 broad domains: Physical Health, Psychological Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. For the Social Relationships domain (3 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Social Relationships score was calculated by summing the 3 scores (#s 20, 21, and 22) and dividing by the total number of questions (3). This result was multiplied by 4 to get a final Social Relationships domain score. Social Relationships raw scoring ranges from 3-15; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 1 participant in the IN-OXT arm and 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 3 (Social Relationships) | 0.00 score on a scale | Standard Deviation 1.8 |
| Placebo Comparator: Matched Placebo | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 3 (Social Relationships) | 0.0714 score on a scale | Standard Deviation 2.43 |
Secondary
Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 4 (Environment)
Change in QOL and caregiver burden was assessed using the abbreviated WHOQOL-BREF. The WHOQOL-BREF is comprised of 26 items which measure 4 broad domains: Physical Health, Psychological Health, Social Relationships, and Environment. The questionnaire was completed by the parent/caregiver and quantified the burden placed on the caregiver/family by the PWS disorder. For the Environment domain (8 questions), responses were assigned to corresponding predefined scores ranging from 1-5 points. A mean overall Environment score was calculated by summing the scores from the 8 questions (#s 8, 9, 12, 13, 14, 23, 24, and 25) and dividing by the total number of questions (8). This result was multiplied by 4 to get a final Environmental domain score. Environment raw scoring ranges from 8-40; however, for purposes of this outcome measure change from baseline was reported. Positive values were associated with higher QOL and reduced caregiver burden.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was missing or unable to be collected from 1 participant in the IN-OXT arm and 3 participants in the matched Placebo study arm (including the 2 participants who withdrew from the study).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 4 (Environment) | -0.0714 score on a scale | Standard Deviation 1.86 |
| Placebo Comparator: Matched Placebo | Change in Quality of Life (QOL) and Caregiver Burden as Determined by the World Health Organization Quality of Life (WHOQOL-BREF) Questionnaire - Domain 4 (Environment) | 0.571 score on a scale | Standard Deviation 4.5 |
Secondary
Change in Repetitive Behavior
Change in Repetitive Behavior from baseline was determined using the Repetitive Behavior Scale Revised (RBS-R) score. The RBS-R is a 44-item form used to measure the full spectrum of repetitive behavior of participants. The child's parent will choose a score that describes how much of a problem the behavior has been over the last month on a 4-point scale ranging from 0 (Behavior does not occur) to 3 (Behavior occurs and is severe problem). The final question asks participants to lump together all behaviors described in the RBS-R, and provide a rating (0-100) for how much of a problem these repetitive behaviors are overall: 1 (Not a problem at all) to 100 (As bad as you can imagine). For purposes of this outcome, a change in group mean score from baseline is summarized. A negative score is indicative of a decrease in the frequency and severity of behavioral problems; whereas, a positive score is indicative of an increase in the frequency and severity of behavioral problems.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Repetitive Behavior | -13.2 score on a scale | Standard Deviation 14.4 |
| Placebo Comparator: Matched Placebo | Change in Repetitive Behavior | -8.53 score on a scale | Standard Deviation 8.89 |
Secondary
Change in Rigid Behavior
Change in Rigid Behavior from baseline was assessed using the Montefiore-Einstein Rigidity Scale-Revised-Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is designed to assess 3 domains of rigid behavior in children with PWS: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity (e.g., verbal objection, tantrum, physical aggression). Four items are rated on a 5-point scale ranging from 0 (No/None) to 4 (Extreme/Extremely difficult) for each of the 3 domains. The domains are added yielding a possible Total Domain Score which could range from 0-48. For purposes of this outcome measure, a change in group mean score from baseline is summarized. A negative score is indicative of a decrease in rigid behaviors from baseline; whereas, a positive score is indicative of an increase in rigid behavior from baseline.
Time frame: From Randomization at Baseline until Endpoint at Week 8 (Change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Change in Rigid Behavior | -8.43 score on a scale | Standard Deviation 5.15 |
| Placebo Comparator: Matched Placebo | Change in Rigid Behavior | -11.2 score on a scale | Standard Deviation 7.86 |
Secondary
Change in Salivary Oxytocin Concentration
Change in Salivary Oxytocin concentration levels from baseline were to have been collected. Salivary samples were to have been collected using the Oragene-Discover collection kit (ORG-500). If able, participants were to have spit saliva directly into the collection tube during an in office or remote visit, and subsequently transported to the clinical site during visit and later processed and submitted for analysis. Change in group mean concentrations from baseline was to have been summarized by study arm using basic descriptive statistics. Increases in concentrations of salivary oxytocin are generally correlated with central nervous system effects and an improvement in these symptoms.
Time frame: From Baseline until collections at 1 hour (Day 1), Week 4 and Week 8
Population: Due to challenges in collecting saliva samples from this population, participants were not able to provide enough saliva to allow for appropriate analysis. As such, samples were not obtained and data was unable to be collected.
Secondary
Clinical Global Impression Scale - Improvement (CGI-I)
CGI-I is a clinician rated global measure of improvement that requires the clinician to assess how much the patient's illness has improved or worsened relative to baseline at the beginning of the intervention. The CGI-I consists of one query which is rated on a 7-point scale: Compared to the patient's condition at admission \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Scores are summarized by study arm using basic descriptive statistics.
Time frame: 8 weeks (measuring change over 8 weeks)
Population: Data was unable to be collected from 2 participants in the matched Placebo study arm who withdrew from the study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) | Clinical Global Impression Scale - Improvement (CGI-I) | 2.93 score on a scale | Standard Deviation 0.884 |
| Placebo Comparator: Matched Placebo | Clinical Global Impression Scale - Improvement (CGI-I) | 3.00 score on a scale | Standard Deviation 1 |